Infectious clone for expressing malaria antigen and application of infectious clone
By integrating the 3D7 ring sporozoite protein and hepatitis B surface antigen gene into the measles virus vector, infectious clones are constructed to form virus-like particles expressing ring sporozoite proteins, the insufficient protection efficiency of existing malaria vaccines is solved. The problem has achieved low-cost and efficient production and promotion of malaria vaccines.
Patent Information
- Application Number
- CN202411161028.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-29
AI Technical Summary
The existing malaria vaccines have not met the effective standard for protection against Plasmodium falciparum, especially in infants, and no recombinant measles is found by constructing the CSP protein and HBsAg into the antigenome of the measles virus. Vehicle vaccine.
The gene fragment encoding the 3D7 ring sporozoite protein of Plasmodium falciparum is integrated with the surface antigen gene of hepatitis B into the measles virus vector, and infectious clones are constructed through the measles virus vector to form hepatitis B virus-like particles expressing ring sporozoite protein. Thus, a recombinant vector vaccine is prepared to prevent malaria.
The production of viral-like particles expressing cyclosporozoite proteins during the replication of measles virus has been achieved, which has reduced production costs and shortened the production cycle. The quality of the vaccine is stable and controllable, suitable for large-scale promotion, and improved the effect of malaria prevention.
Smart Images

Figure CN119040348A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of gene recombination vaccines, and in particular relates to an infectious clone expressing malaria antigens and an application thereof. Background Art
[0002] Measles virus (MV) is the pathogen of measles and belongs to the genus Morbillivirus of the family Paramyxoviridae. Measles is a common acute infectious disease in children. It is highly contagious and is characterized by skin papules, fever and respiratory symptoms. If there are no complications, the prognosis is good. Since the application of attenuated live vaccines in my country in the early 1960s, the incidence of measles in children has dropped significantly. However, it is still a major cause of death among children in developing countries.
[0003] MV vectors include vaccine strains such as Shanghai 191, Edmonston B, Edmonston Zagreb, and Schwarz. On this basis, recombinant MV vector vaccines expressing the spike protein of the new coronavirus and the antigen protein of the chikungunya virus (CHIKV) have been developed. The CHIKV envelope protein binds to MV to produce CHIKV virus-like particles (VLPs), which show a strong antigen-specific T cell response and have a protective effect. The MV-CHIKV vaccine has successfully completed Phase II clinical trials and will be ready to enter Phase III clinical trials. Because the recombinant MV vaccine induces long-term, strong humoral and cellular immune responses, and MV is combined with pathogens transmitted through body fluids such as hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus HPV16 and HPV18 or Helicobacter pylori, these recombinant MV vaccines have shown significant antibody responses in animal experiments, proving the high immune-inducing ability of attenuated MV.
[0004] Plasmodium is a unicellular eukaryotic organism. There are five main types of malaria parasites that infect humans: Plasmodium falciparum, P.vivax, P.malariae, P.ovale, and P.knowlesi. Plasmodium falciparum has a high mortality rate and can multiply rapidly in the blood, causing fatal cerebral malaria. Circumsporozoite surface protein (CSP) is the first antigen developed on Plasmodium sporozoites. CSP consists of three parts: an N-terminal region (RI) linked to heparin sulfate proteoglycan, a middle region containing a tetraamino acid repeat sequence (NANP), and a GPI-anchored C-terminal region containing a thrombin-spondin-like domain (RII). RTS,S / AS01E, which has been pre-certified and recommended by WHO, is composed of the last 16 NANP repeats of CSP, the C-terminal sequence containing T cell epitopes and the hepatitis B virus surface antigen (HBsAg) fused to form RTS in yeast expressing HBsAg, spontaneously assembled with HBsAg to form virus-like particles (VLPs), and combined with adjuvant AS01E. The Phase III clinical trial of RTS,S / AS01E administered 0.5mL per intramuscular injection, three times with an interval of one month, and then the fourth injection 18 months after the third dose. After four doses, the incidence of clinical malaria in infants decreased by 26%, and the incidence of clinical malaria in young children decreased by 36%. It has a statistically significant effect on severe malaria in young children, but not in infants. The protection efficiency has not reached the standard of an effective malaria vaccine, that is, the protection efficiency is greater than 50% and the duration is more than 1 year.
[0005] Based on RTS,S / AS01E, the R21 malaria vaccine developed by the Jenner Institute in the UK reduced the proportion of HBsAg in VLP and increased the proportion of CSP. TM The Phase III clinical safety and efficacy trial (NCT04704830) showed that after 3 injections of 5μgR21 / 50μgMM immunization in children aged 5-36 months, the efficacy (occurrence of clinical malaria) was 75% in seasonal locations (locations with high seasonal malaria transmission rates) within 12 months, and the efficacy was 68% in standard locations (locations where malaria is transmitted all year round), which was the first to reach the 75% efficacy target set by the World Health Organization. It has now passed the pre-certification of the World Health Organization.
[0006] Recombinant vector vaccine is a new type of vaccine that integrates multiple viral genes. The principle is: insert the neutralizing epitope gene fragment of virus A into the genome of virus B to obtain a recombinant virus that can express the neutralizing antigen of virus A (or further form virus-like particles of virus A), which can induce the body to produce corresponding antibodies and memory B cells and T cells against viruses A and B. The vaccine prepared by using this recombinant virus as an immunogen is the recombinant vector vaccine. The recombinant vector vaccine only needs to cultivate a strain, prepare a high-titer virus, and select a freeze-drying stabilizer and freeze-drying process for the virus.
[0007] At present, there is no recombinant measles vector vaccine that incorporates Plasmodium falciparum CSP protein and HBsAg (to form virus-like particles) into the measles virus antigenome. Summary of the invention
[0008] The purpose of the present invention is to integrate the gene fragment encoding the circumsporozoite protein of Plasmodium falciparum 3D7 and the hepatitis B surface antigen gene, so as to obtain infectious clones through measles virus vectors, and after virus rescue, hepatitis B virus surface antigen virus-like particles expressing the circumsporozoite protein can be obtained, thereby preparing a recombinant vector vaccine for preventing malaria.
[0009] The present invention provides a gene fragment, the nucleotide sequence of which is shown as SEQ ID NO.2.
[0010] The present invention also provides an infectious clone expressing a malarial antigen, which is a recombinant vector connected with a nucleotide sequence such as SEQID NO.2;
[0011] The recombinant vector includes the measles virus antigenome sequence.
[0012] Furthermore, the gene fragment with the nucleotide sequence as shown in SEQ ID NO.2 is located in an additional transcription unit between the P gene and the M gene in the measles virus antigenome.
[0013] Furthermore, it is a measles virus vector connected with a nucleotide sequence such as SEQ ID NO.2.
[0014] Furthermore, the measles virus vector is a vector constructed with the antigenome of the Edmonston Zagreb vaccine strain;
[0015] The construction method of the vector is:
[0016] The 5' end of the antigenome of the measles Edmonston Zagreb vaccine strain is inserted with a T7 promoter and a hammerhead nuclease sequence, the 3' end of the antigenome is inserted with a T7 terminator and a hepatitis D virus ribozyme sequence, an additional transcription unit is introduced between the P gene and the M gene, and finally the modified antigenome of the measles Edmonston Zagreb vaccine strain is connected to the pT7-MCS vector to obtain;
[0017] The nucleotide sequence of the additional transcription unit is shown in SEQ ID NO.3.
[0018] The present invention also provides a recombinant virus, which is a recombinant measles virus carrying a gene fragment with an expression nucleotide sequence as shown in SEQ ID NO.2.
[0019] Furthermore, it is replicated and packaged after the aforementioned infectious clone and four helper plasmids are co-transfected into host cells;
[0020] The four auxiliary plasmids carry the genes for expressing measles N protein, measles P protein, measles L protein and T7 RNA polymerase.
[0021] Furthermore, the host cells include BSR-T7 cells and / or Vero cells.
[0022] Furthermore, the transfection is carried out by Lipofectamine 3000 reagent transfection.
[0023] Furthermore, the mass volume ratio of the infectious clone to the plasmid expressing measles N protein, measles P protein, measles L protein and T7 RNA polymerase, and Lipofectamine 3000 reagent is 12 μg: 8 μg: 4 μg: 1 μg: 4 μg: 0.075 ml.
[0024] The present invention also provides a use of the aforementioned recombinant virus in preparing a drug for preventing and / or treating malarial infection.
[0025] Finally, the present invention provides a vaccine for preventing malaria, which is prepared by taking the aforementioned recombinant virus as antigen and adding pharmaceutically acceptable excipients.
[0026] The "antigenome sequence" of the present invention refers to the reverse complementary sequence of the viral genome, which is generally DNA. Since measles virus is an RNA virus, it is technically difficult to directly use the genomic RNA to construct a plasmid, so the antigenome sequence (DNA form) of measles virus is used.
[0027] The present invention connects the gene fragment encoding the circumsporozoite protein of Plasmodium falciparum 3D7 and the hepatitis B surface antigen gene through a specific flexible fragment gene, and inserts the infectious clone obtained in the measles virus vector, and obtains the hepatitis B virus surface antigen virus-like particles expressing the circumsporozoite protein through virus rescue. The vaccine prepared by expressing the virus-like particles as the measles virus replicates has low production cost, fast production cycle, stable and controllable quality, and is suitable for large-scale promotion and use in the crowd. Therefore, the recombinant malaria vaccine of the present invention has good application prospects.
[0028] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0029] The above contents of the present invention are further described in detail below through specific implementation modes in the form of examples, but it should not be understood that the scope of the above subject matter of the present invention is limited to the following examples. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 :RT-PCR identification of MVEZ-CSP recombinant virus.
[0031] Figure 2 :Detection of MVEZ-CSP recombinant virus CSP protein. 1: MVEZ-CSP bright field; 2: MVEZ-CSP fluorescence; 3: negative control illumination field; 4: negative control fluorescence.
[0032] Figure 3 :Western blot analysis of MVEZ-CSP purified samples. 1: Diamond Q Mustang eluted samples treated with reducing buffer; 2: Diamond Q Mustang eluted samples treated with non-reducing buffer.
[0033] Figure 4 :SDS-PAGE detection of MVEZ-CSP purified samples. 1: Diamond Q Mustang eluted samples treated with reducing buffer; 2: Diamond Q Mustang eluted samples treated with non-reducing buffer.
[0034] Figure 5 : Particle morphology of Diamond Q Mustang eluted sample observed under transmission electron microscope.
[0035] Figure 6 : Growth curves of MVEZ-CSP at different MOIs from day 1 to day 10, with time as the abscissa and titer as the ordinate. DETAILED DESCRIPTION
[0036] The reagents and equipment used in the specific embodiments of the present invention are all known products, which are obtained by purchasing commercially available products. The plasmids used are as follows:
[0037] pT7-IRES-MVN plasmid: Takara pT7-IRES His-C DNA was used as a vector, and the measles N protein (MVN) gene was inserted into the multiple cloning site. The nucleotide sequence of the MVN gene is 56 to 1685 nucleotides as shown in GenBank: FJ416067.1;
[0038] pT7-IRES-MVP plasmid: Takara pT7-IRES His-C DNA was used as a vector, and the measles P protein (MVP) gene was inserted into the multiple cloning site. The nucleotide sequence of the MVP gene is nucleotides 1748 to 3402 as shown in GenBank: FJ416067.1;
[0039] pT7-IRES-MVL plasmid: Takara pT7-IRES His-C DNA was used as a vector, and the measles L protein (MVL) gene was inserted into the multiple cloning site. The nucleotide sequence of the MVL gene is nucleotides 9212 to 15854 as shown in GenBank: FJ416067.1;
[0040] pCAGGS-T7RNAP plasmid: pCAGGS is used as a vector, and the T7 RNA polymerase gene is inserted into the multiple cloning site. The nucleotide sequence of the T7 RNA polymerase gene is shown in GenBank: MK567984.1.
[0041] Example 1 Construction of recombinant virus
[0042] 1. Construction of the infectious clone pT7MVEZ-CSP of the recombinant virus
[0043] Preliminary experiments found that the fragments (from 193 amino acids to 376 amino acids) encoding the Plasmodium falciparum 3D7 circumsporozoite protein (NCBI Reference Sequence: XP_001351122.1) gene and the hepatitis B surface antigen (GenBank: CAA10045.1) gene after codon optimization in the mammalian cell eukaryotic system need to be connected through flexible fragment genes, and the gene fragments connected by different linkers, when constructed by measles virus vectors, may not necessarily rescue virus-like particles with infectious activity during virus rescue. Only the Plasmodium falciparum 3D7 circumsporozoite protein gene and the hepatitis B surface antigen gene connected with the following flexible fragment gene as a linker can perform well during virus rescue.
[0044] The specific nucleotide sequence of the flexible fragment gene is SEQ ID NO.1
[0045]
[0046] After the connection, the BsiWI restriction site and ATG start codon were introduced at the 5' end of the gene, and the BssHII restriction site, TGA and TAA stop codons were introduced at the 3' end to ensure that the number of bases from the BsiWI restriction site to the BssHII restriction site was a multiple of 6. The nucleotide sequence was synthesized by GenScript Biotech. BsiWI and BssHII restriction endonuclease sites were added to both ends of the genes encoding the circumsporozoite protein and the hepatitis B virus surface antigen protein, respectively. The fragment was inserted into the additional transcription unit (ATU) between P and M of the measles virus vector through the BsiWI and BssHII restriction sites to construct the infectious clone pT7MVEZ-CSP of the recombinant measles virus expressing the falciparum Plasmodium circumsporozoite protein virus-like particles, which was constructed and prepared by GenScript Biotech. The full-length nucleotide sequence of the gene fragment specifically inserted into the measles virus vector is SEQ ID NO.2:
[0047]
[0048]
[0049] The measles virus vector used above is a vector constructed with the antigenome of the Edmonston Zagreb vaccine strain. The specific construction method is as follows: the T7 promoter and hammerhead nuclease sequence (HamRz) are inserted into the 5' end of the antigenome of the measles Edmonston Zagreb vaccine strain, the T7 terminator and hepatitis D virus ribozyme sequence (HdvRz) are inserted into the 3' end of the antigenome, and an additional transcription unit (ATU) is introduced between the P gene and the M gene. The modified antigenome of the measles Edmonston Zagreb vaccine strain is constructed into the pT7-MCS vector. The nucleotide sequence of ATU is SEQ ID NO.3:
[0050] GTCGACCCAACTAGCCTACCCTCCATCATTGTTATAAAAAACTTAGGAACCAGGTCCACACAGCCGCCAGCCCATCAACG CGTACG ATGGTGAGCAAGGGCGAGGAGCTGTTCACCACTCTCGGCATGGACGAGCTGTACAAGTAG GCGCGC AGCGCTTAGACGTCTCGCGACTAGT
[0051] Note: The first underlined part is the BsiWI restriction site, and the restriction site is after the first C base of the underline; the second underlined part is the BssHII restriction site, and the restriction site is after the first G base of the underline.
[0052] 2Virus rescue
[0053] BSR-T7 cells were plated in a 6-well plate. The next day, 12 μg of pT7MVEZ-CSP and 8 μg of pT7-IRES-MVN plasmid, 4 μg of pT7-IRES-MVP, 1 μg of pT7-IRES-MVL, and 4 μg of pCAGGS-T7RNAP auxiliary plasmid were mixed. The virus was rescued by 0.075 ml of Lipofectamine 3000 reagent. 8 hours after transfection, 2 ml of DMEM containing 2% NBS was replaced and cultured at 37°C with 5% CO2 for 36 hours. The supernatant was transferred to a Vero cell T25 culture flask with a confluence of 70-80% and adsorbed for 4 hours. After that, 10 ml of MEM containing 2% NBS was replaced and cultured for another 4 days before observing the lesions. When the cell lesions were about 80-90%, the lesion cells and supernatant mixture were repeatedly frozen and thawed 3 times. The liquid after freezing and thawing was the recombinant virus MVEZ-CSP.
[0054] 3. Detection of exogenous genes of recombinant measles virus
[0055] 3.1 RT-PCR identification of exogenous genes
[0056] Take the virus culture medium, extract the genomic RNA of the recombinant virus according to the instructions of the Foregene virus RNA extraction kit, and reverse transcribe the genomic RNA into cDNA with random primers. Using this cDNA as a template, use Phusion high-fidelity DNA polymerase and primers seq-FOR (SEQ ID NO.4: GCCAAGTTCCACCAGATG) and seq-REV (SEQ ID NO.5: ATCCTTCCTGTCGCCTAG) to amplify the exogenous gene fragment, and send the PCR product to Sangon Biotechnology for sequencing. Figure 1 It can be seen that the gene fragment (1766 bp) expressing CSP and HBsAg can be amplified from the cDNA reverse transcribed from the rescued viral RNA and the fragment size is consistent with the theoretical value.
[0057] 3.2 Immunofluorescence assay to detect the expression of circumsporozoite protein CSP of Plasmodium falciparum
[0058] Vero cells were plated in 12-well plates, cultured in 10% NBS / MEM medium at 37°C, 5% CO2 until the cell confluence was 80%-90%, and inoculated with MVEZ-CSP at MOI = 0.005, 2% NBS / MEM, and cultured at 37°C, 5% CO2 until the cytopathic effect (CPE) reached 80-90%. Cells were fixed with 4% paraformaldehyde, washed with PBS, permeabilized with 1% Triton X-100, and blocked with 5% goat serum / PBST. Recombinant mouse anti-CSP antibody (1:2000) was added and incubated at room temperature for 1 hour. Washed with PBST 3 times, 5 minutes each time. Alexa Fluor488-labeled goat anti-mouse IgG (H+L) (1:1000) was added and incubated at room temperature for 1 hour. Washed with PBST 3 times, 5 minutes each time. The results were observed under a fluorescence microscope. Figure 2 It can be seen that the rescued virus successfully expressed the CSP protein.
[0059] 3.3 Western blot, SDS-PAGE and transmission electron microscopy detection of recombinant virus MVEZ-CSP virus-like particles
[0060] The recombinant virus MVEZ-CSP was expanded in a 7.5L bioreactor, and the virus supernatant was harvested. The flow-through was collected after Diamond Layer400 chromatography, and then purified by Diamond Q Mustang chromatography. The purified recombinant virus MVEZ-CSP virus-like particles were collected and detected by Western blot and SDS-PAGE. The primary antibody was a recombinant mouse anti-PfCSP antibody (2A10). Figure 3 , Figure 4 , Figure 5 As shown, it was shown that the recombinant measles virus MVEZ-CSP successfully assembled VLPs expressing CSP.
[0061] 4. Recombinant virus titer detection and virus growth curve drawing
[0062] The infectious titer of the recombinant virus was detected by the endpoint dilution method, and the cell half infectious dose (CCID50) was calculated by the Reed-Muench method. The recombinant virus was subcultured on Vero cells, and the virus solution was collected by freezing and thawing once at -20°C. The recombinant virus was diluted 10 times in a series of gradients using MEM culture medium, and 100l / well of the virus solution was inoculated into Vero cells cultured in 96-well plates. Each dilution was inoculated in 8 replicates, and the cells were cultured at 37°C and 5% CO2 for 7 days to observe the cytopathic effect, and the titer was calculated by the Reed-Muench method.
[0063] The cells were inoculated with different MOIs, and the supernatant was collected every day from 1 to 10 days after inoculation to detect the virus titer. The data were sorted by GraphPad Prism8, and the growth curve was drawn with time as the horizontal axis and titer as the vertical axis, as shown in the figure. Figure 6 If 10-fold dilution fails to cause pathological changes in Vero cells, the titer is ≤1.5.
[0064] In summary, the MVEZ-CSP recombinant virus was obtained by rescuing the full-length measles plasmid inserted with CSP and HBsAg genes on BSR-T7 cells, and the recombinant virus was amplified and purified by Diamond Layer 400 and Diamond QMustang chromatography, and VLP particles were observed under a transmission electron microscope, proving that the recombinant virus assembled into CSP VLPs, indicating that the recombinant virus has the potential to become a candidate vaccine strain for malaria.
Claims
1. A gene fragment, characterized in that: Its nucleotide sequence is shown in SEQ ID NO.
2.
2. An infectious clone expressing a malarial antigen, characterized in that: It is a recombinant vector connected with a nucleotide sequence such as SEQ ID NO.2; The recombinant vector comprises the measles virus antigenome sequence.
3. The infectious clone according to claim 2, characterized in that: The gene fragment with the nucleotide sequence shown in SEQ ID NO.2 is located in the additional transcription unit between the P gene and the M gene in the measles virus antigenome.
4. The infectious clone according to claim 2 or 3, characterized in that: It is a measles virus vector connected with a nucleotide sequence such as SEQ ID NO.
2.
5. The infectious clone according to claim 4, characterized in that: The measles virus vector is a vector constructed based on the antigenome of the Edmonston Zagreb vaccine strain; The construction method of the vector is: The 5' end of the antigenome of the measles Edmonston Zagreb vaccine strain is inserted with a T7 promoter and a hammerhead nuclease sequence, the 3' end of the antigenome is inserted with a T7 terminator and a hepatitis D virus ribozyme sequence, an additional transcription unit is introduced between the P gene and the M gene, and finally the modified antigenome of the measles Edmonston Zagreb vaccine strain is connected to the pT7-MCS vector to obtain; The nucleotide sequence of the additional transcription unit is shown in SEQ ID NO.
3.
6. A recombinant virus, characterized in that: It is a recombinant measles virus carrying a gene fragment with an expression nucleotide sequence as shown in SEQ ID NO.
2.
7. The recombinant virus according to claim 6, characterized in that: It is formed by co-transfecting host cells with the infectious clone described in any one of claims 1 to 5 and four auxiliary plasmids and then replicating and packaging them; The four auxiliary plasmids carry the genes for expressing measles N protein, measles P protein, measles L protein and T7 RNA polymerase.
8. The recombinant virus according to claim 7, characterized in that: The host cells include BSR-T7 cells and / or Vero cells.
9. Use of the recombinant virus according to any one of claims 6 to 8 in the preparation of a medicament for preventing and / or treating malarial infection.
10. A vaccine for preventing malaria, characterized in that: The vaccine is prepared by using the recombinant virus described in claim 6 as an antigen and adding pharmaceutically acceptable excipients.
